UBS Upgrades Neurocrine Bio Shares Forecast Due to Promising Outlook
Tuesday, 28 May 2024, 06:58
UBS Raises Neurocrine Bio Shares Target on Strong Prospects
Swiss investment bank UBS has raised its target price for Neurocrine Bio shares, highlighting the company's strong growth potential. This upgrade is based on the promising outlook for Neurocrine Bio, indicating favorable market conditions and performance expectations.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.